Autolus Therapeutics PLC (AUTL) Stock Price & News

Why is AUTL down 3.78%?

Dive Deeper

AUTL:NASDAQ

Autolus Therapeutics PLC

$1.78

-3.78%

(-0.070) 1D

$1.80

+1.12% (+0.020)

After hours

Closed: Oct 2, 4:00:01 PM GMT-4 · USD

All symbols

	Symbol	Price	Change	% Change

Generating top insights for AUTL...

Open

$1.85

High

$1.88

Low

$1.76

Mkt. cap

473.77M

Avg. vol.

1.63M

Volume

1.81M

52-wk high

$2.58

52-wk low

$1.18

EPS

-$1.05

Beta

2.15

Shares outstanding

266.16M

No. of employees

753

Open

$1.85

High

$1.88

Low

$1.76

Mkt. cap

473.77M

Avg. vol.

1.63M

Volume

1.81M

52-wk high

$2.58

52-wk low

$1.18

EPS

-$1.05

Beta

2.15

Shares outstanding

266.16M

No. of employees

753

Related stocks

Space Exploration Technologies Corp

$158.96

+7.35%

News stories

From web sources and news partners

Traders Union

34 minutes ago

S&P500 has posted gains in nearly every November-through-June period since 1942, Lia Holmgren notes

Simply Wall Street

1 hour ago

What Was Actually At Stake In Kanzhun's 34% Slide

TradingView

2 hours ago

Getty Images Delists From NYSE, Shares Begin Trading Over The Counter Market

AOL.com

8 hours ago

History Says Stocks Typically Fall After a Fed Hike Cycle Begins -- Then Gain 6.8% Within a Year. Here's My Plan.

About Autolus Therapeutics PLC

CEOChristian Itin

Employees753

Founded2014

Headquarters-

SectorBiotechnology

Websiteautolus.com

Analyst	Recommendation	Action	Price target	Projected	Date
Gil Blum Needham	Buy	Maintained	$10.00	+461.8%	10/02/2026
Matt Phipps William Blair	Buy	Reiterated	-	-	09/25/2026
Emily Bodnar H.C. Wainwright	Buy	Maintained	$10.00	+461.8%	09/21/2026
Unknown Analyst Wells Fargo	Buy	Reiterated	$5.00	+180.9%	08/12/2026
Rajan Sharma Goldman Sachs	Buy	Reiterated	$5.80	+225.8%	08/11/2026
Salim Syed Mizuho Securities	Buy	Maintained	$10.00	+461.8%	06/10/2026
Unknown Analyst Goldman Sachs	Buy	Reiterated	$5.40	+203.4%	05/15/2026

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	21.19M	24.29M	26.22M	45.69M
Cost of goods sold	56.54M	54.29M	45.78M	48.37M
Cost of revenue	56.54M	54.29M	45.78M	48.37M
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	36.28M	42.12M	39.95M	41.16M
Operating expense	36.28M	42.12M	39.95M	41.16M
Total operating expenses	92.82M	96.41M	85.73M	89.53M
Operating income	-71.62M	-72.12M	-59.51M	-43.84M
Other non operating income	84.00K	-11.66M	100.00K	15.35M
EBT including unusual items	-78.59M	-91.52M	-70.74M	-38.65M
EBT excluding unusual items	-78.59M	-91.17M	-70.74M	-38.65M
Income tax expense	532.00K	-1.18M	863.00K	465.00K
Effective tax rate	-0.68%	1.29%	-1.22%	-1.20%
Other operating expenses	-	-	-	-
Net income	-79.12M	-90.33M	-71.60M	-39.11M
Net profit margin	-373.30%	-371.90%	-273.09%	-85.60%
Earnings per share	-0.30	-0.34	-0.27	-0.15
Interest and investment income	4.38M	3.23M	2.47M	1.88M
Interest expense	-10.52M	-11.01M	-11.12M	-12.50M
Net interest expenses	-6.14M	-7.78M	-8.66M	-10.62M
Depreciation and amortization charges	-	-	-	-
EBITDA	-69.08M	-69.49M	-56.81M	-41.19M
Gain or loss from assets sale	-	11.00K	2.00K	-

Finance

Ask anything